ERBB2 and breast cancer: In addition, a preclinical study revealed that inhibition of HER3 expression combined with lapatinib reduced MMTV-Neu mice tumor growth to a greater extent than either HER3 inhibition or lapatinib alone [91], suggesting the potential of HER3-containing combination regimens in treating HER2-overexpressing breast cancers.